Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Application of Fluorescence Imaging in Cancer
share announcement

Application of Fluorescence Imaging in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 1241

Special Issue Editor

Dr. He Nucleus Xu

E-Mail Website
Guest Editor
Britton Chance Laboratory of Redox Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Interests: fluorescence imaging; cancer metabolism; cancer immunotherapy; NAD supplementation; bronchopulmonary dysplasia; neurodegenerative disorder

Special Issue Information

Dear Colleagues,

As a crucial component of cancer research, fluorescence imaging includes the visualization of the autofluorescence or intrinsic fluorescence of intracellular metabolites, externally administered chemical fluorescence probes, and genetically engineered fluorescence indicators, etc. This technology also plays an important role in certain surgical procedures, providing real-time insights. Fluorescence imaging serves as a versatile tool for researchers, facilitating mechanistic investigations, the identification of cancer diagnostic and prognostic biomarkers, the discovery of druggable targets, and the exploration of interactions between tumor cells and immune cells, tracking circulating cancer cells. These applications are merely a glimpse into its diverse utility. Given the extensive scope of its utility in cancer research and clinical applications, there is a compelling case for the creation of a dedicated Special Issue. This Special Issue will serve as a platform for the dissemination of the latest findings and breakthroughs in the various applications of fluorescence imaging within the context of cancer, fostering continued advancements in this dynamic field.

This Special Issue welcomes original research articles, comprehensive review or insightful commentary articles on previous studies in the realm of cancer research (cellular, tumor animal models), or clinical applications (real-time, biopsy, FFPE sections) focusing on the following areas: (1) imaging of the autofluorescence or intrinsic fluorescence of intracellular metabolites, either intensity-based or fluorescence lifetime-based; (2) development of, or by using, any types of fluorescence probes or reporters; (3) development of instrumentation for fluorescence imaging; (4) fluorescence spectroscopic studies that contribute to the improvement of fluorescence imaging; (5) (AI-assisted) fluorescence imaging analysis techniques. 

Dr. He Nucleus Xu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NADH and FAD
  • redox ratio
  • chemical fluorescence probes
  • genetically engineered fluorescence indicators/reporters
  • fluorescence imaging analysis
  • fluorescence imaging instrumentation
  • fluorescence imaging of treatment response
  • fluorescence imaging in immunotherapy
  • fluorescence imaging in surgery

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3673 KiB  
Article
Quantitative Optical Redox Imaging of Melanoma Xenografts with Different Metastatic Potentials
by April Peng, He N. Xu, Lily Moon, Paul Zhang and Lin Z. Li
Cancers 2024, 16(9), 1669; https://doi.org/10.3390/cancers16091669 - 25 Apr 2024
Viewed by 485
Abstract
To develop imaging biomarkers for tumors aggressiveness, our previous optical redox imaging (ORI) studies of the reduced nicotinamide adenine dinucleotide (NADH) and oxidized flavoproteins (Fp, containing flavin adenine dinucleotide, i.e., FAD) in tumor xenografts of human melanoma associated the high optical redox ratio [...] Read more.
To develop imaging biomarkers for tumors aggressiveness, our previous optical redox imaging (ORI) studies of the reduced nicotinamide adenine dinucleotide (NADH) and oxidized flavoproteins (Fp, containing flavin adenine dinucleotide, i.e., FAD) in tumor xenografts of human melanoma associated the high optical redox ratio (ORR = Fp/(Fp + NADH)) and its heterogeneity to the high invasive/metastatic potential, without having reported quantitative results for NADH and Fp. Here, we implemented a calibration procedure to facilitate imaging the nominal concentrations of tissue NADH and Fp in the mouse xenografts of two human melanoma lines, an indolent less metastatic A375P and a more metastatic C8161. Images of the redox indices (NADH, Fp, ORR) revealed the existence of more oxidized areas (OAs) and more reduced areas (RAs) within individual tumors. ORR was found to be higher and NADH lower in C8161 compared to that of A375P xenografts, both globally for the whole tumors and locally in OAs. The ORR in the OA can differentiate xenografts with a higher statistical significance than the global averaged ORR. H&E staining of the tumors indicated that the redox differences we identified were more likely due to intrinsically different cell metabolism, rather than variations in cell density. Full article
(This article belongs to the Special Issue Application of Fluorescence Imaging in Cancer)
►▼ Show Figures

Figure 1

17 pages, 4370 KiB  
Article
Ex Vivo Fluorescence Confocal Microscopy of MRI-Guided Targeted Prostate Biopsies for Rapid Detection of Clinically Significant Carcinomas—A Feasibility Study
by Ulf Titze, Barbara Titze, Torsten Hansen, Peter J. Barth, Furat Abd Ali, Fried Schneider, Matthias Benndorf and Karl-Dietrich Sievert
Cancers 2024, 16(5), 873; https://doi.org/10.3390/cancers16050873 - 22 Feb 2024
Viewed by 573
Abstract
Background: MRI-guided prostate biopsies from visible tumor-specific lesions (TBx) can be used to diagnose clinically significant carcinomas (csPCa) requiring treatment more selectively than conventional systematic biopsies (SBx). Ex vivo fluorescence confocal microscopy (FCM) is a novel technique that can be used to examine [...] Read more.
Background: MRI-guided prostate biopsies from visible tumor-specific lesions (TBx) can be used to diagnose clinically significant carcinomas (csPCa) requiring treatment more selectively than conventional systematic biopsies (SBx). Ex vivo fluorescence confocal microscopy (FCM) is a novel technique that can be used to examine TBx prior to conventional histologic workup. Methods: TBx from 150 patients were examined with FCM on the day of collection. Preliminary findings were reported within 2 h of collection. The results were statistically compared with the final histology. Results: 27/40 (68%) of the csPCa were already recognized in the intraday FCM in accordance with the results of conventional histology. Even non-significant carcinomas (cisPCa) of the intermediate and high-risk groups (serum prostate-specific antigen (PSA) > 10 or 20 ng/mL) according to conventional risk stratifications were reliably detectable. In contrast, small foci of cisPCa were often not detected or were difficult to distinguish from reactive changes. Conclusion: The rapid reporting of preliminary FCM findings helps to reduce the psychological stress on patients, and can improve the clinical management of csPCa. Additional SBx can be avoided in individual cases, leading to lower rates of complications and scarring in the future surgical area. Additional staging examinations can be arranged without losing time. FCM represents a promising basis for future AI-based diagnostic algorithms. Full article
(This article belongs to the Special Issue Application of Fluorescence Imaging in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop